Krystal Biotech Inc (KRYS) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.

Total Cash From Operating Activities Chart for Krystal Biotech Inc

Krystal Biotech Inc (KRYS) operating cash flow for FY2025 was USD 200.9M, a 62.7% change from FY2024. Krystal Biotech Inc's operating cash flow moved from USD -1.3M in 2016 to USD 200.9M in 2025 over 9 years.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$9.67B
Implied Share Price
$326.81
Enterprise Value
$9.28B
Revenue (TTM)
$440.48M
EBITDA
$199.29M
Profit Margin
54.82%
Trailing P/E
40.95
Forward P/E
46.95
Price/Book (MRQ)
7.44
Price/Sales (TTM)
21.96
EV/EBITDA
45.39
EV/Revenue
21.06
Dividend Yield
—
Book Value
$45.92
Free Cash Flow (FY2025)
$188.91M
Free Cash Flow Yield
1.95%

Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.